Avacta Group (AVCT)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

44.10p
   
  • Change Today:
      0.100p
  • 52 Week High: 159.60p
  • 52 Week Low: 41.00p
  • Currency: UK Pounds
  • Shares Issued: 359.04m
  • Volume: 873,148
  • Market Cap: £158.34m
  • RiskGrade: 461

Avacta doses first patient in higher-dose oncology cohort

By Josh White

Date: Wednesday 05 Apr 2023

LONDON (ShareCast) - (Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.
The AIM-traded firm said the development came after the Medical and Healthcare products Regulatory Agency (MHRA) approved an amended clinical trial protocol to allow for higher levels of dosing.

Its safety data monitoring committee (SDMC) recommended that the phase 1a dose escalation clinical trial continue to a fifth dose cohort at 250mg per square metre, after observing a favourable safety profile for AVA6000 generated in the study so far.

The escalation to that level of dosing would fall outside of the original clinical trial protocol, and thus the protocol required amendment and approval by the MHRA.

"We are very much encouraged by the positive safety and tolerability data emerging from the dose escalation phase 1a study of AVA6000," said chief executive officer Dr Alastair Smith.

"Following the recommendation from the SDMC, and approval by the MHRA, we are pleased to commence dosing in the fifth patient cohort of this trial.

"The recent confirmation of release of active chemotherapy in the tumour tissue and the safety data being generated in the ALS-6000-101 study are providing detailed insights into the 'preCISION' platform which add significant value to the technology and confirm the tumour targeting potential of the platform."

At 1312 BST, shares in Avacta Group were up 4.52% at 121.24p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Avacta Group Market Data

Currency UK Pounds
Share Price 44.10p
Change Today 0.100p
% Change 0.23 %
52 Week High 159.60p
52 Week Low 41.00p
Volume 873,148
Shares Issued 359.04m
Market Cap £158.34m
RiskGrade 461

Avacta Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
33.69% below the market average33.69% below the market average33.69% below the market average33.69% below the market average33.69% below the market average
49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average
Price Trend
86.1% below the market average86.1% below the market average86.1% below the market average86.1% below the market average86.1% below the market average
51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average
Income Not Available
Growth
62.97% above the market average62.97% above the market average62.97% above the market average62.97% above the market average62.97% above the market average
82.35% above the sector average82.35% above the sector average82.35% above the sector average82.35% above the sector average82.35% above the sector average

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 0
Strong Sell 1
Total 3
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Avacta Group Dividends

No dividends found

Trades for 24-May-2024

Time Volume / Share Price
17:11 22,500 @ 44.10p
16:35 500 @ 44.10p
16:35 500 @ 44.10p
16:29 100,000 @ 42.70p
16:26 2,000 @ 42.95p

Avacta Group Key Personnel

CFO Tony Peter Gardiner
CEO Christina Coughlin

Top of Page